Biotech reverse mergers surge 1,600% in Q3, matching number of IPOs in 2026

Biotech companies are turning to reverse mergers as a faster, less volatile route to the public markets. In the third quarter of 2026, 17 reverse mergers were completed or announced, a 1,600% increase from the single transaction reported in the previous quarter.

By the end of the year, the total count of reverse mergers (19) is almost equal to the 20 traditional biotech IPOs recorded so far. The surge means that reverse mergers are now a comparable pathway to raising capital and gaining market visibility.

Jack Bannister of Leerink Partners highlighted that the market often overlooks these deals, noting that they are “under the radar” but have become as common as IPOs this year. The trend reflects a shift toward alternative financing structures, including de‑SPAC transactions, as companies seek quicker access to public investors.

Analysts suggest that the growing use of reverse mergers could reshape how biotech firms approach public listings, offering a viable option when traditional IPO windows are tight or market conditions are uncertain.